Literature DB >> 23697348

Atypical erythema migrans in patients with PCR-positive Lyme disease.

Steven E Schutzer, Bernard W Berger, James G Krueger, Mark W Eshoo, David J Ecker, John N Aucott.   

Abstract

Entities:  

Keywords:  Borrelia burgdorferi; Lyme disease; PCR; bacteria; bull’s-eye rash; erythema migrans; rash

Mesh:

Substances:

Year:  2013        PMID: 23697348      PMCID: PMC3647494          DOI: 10.3201/eid1905.120796

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: The best diagnostic sign in patients with early Lyme disease is a skin lesion, erythema migrans (EM). However this sign may not occur or be recognized in 30% of cases (). Furthermore, the EM rash may not display a classic bull’s-eye (ring-within-a-ring) appearance, a fact that may be underappreciated (,). Some studies noted uncharacteristic variants of EM in 25%–30% of cases (–). One study reported the rash to be uniformly red in 60% of cases (). Other atypical variants of EM are a blue-red appearance and, occasionally, a vesicular central region (,). We describe the occurrence of atypical EM in patients with microbiologically proven Borrelia burgdorferi infection. During spring and summer 2009, a total of 29 patients with classic or possible EM and suspected Lyme disease were referred by primary care physicians for an ongoing prospective study. Laboratory methods have been described (). The patients were >18 years of age and lived in suburban Baltimore, Maryland, USA, where Lyme disease is endemic. All patients had extracutaneous manifestations (e.g., virus-like symptoms). Fourteen patients met laboratory criteria for study analysis: 1) positive PCR at the initial study visit, detected by a B. burgdorferi–specific nucleic acid–enhancing PCR method on a 1.25-mL whole blood sample (), and 2) evidence of B. burgdorferi exposure by the 2-tiered antibody test at the initial or posttreatment visit. Other entry criteria were a rash >5 cm and symptoms compatible with early Lyme disease (); exclusion criteria were certain preexisting medical conditions (). A panel of experienced specialists, including dermatologists, were shown photographs of the patientsskin lesions and asked if they would expect the average primary care physician to diagnose the lesions as EM. To avoid bias, PCR and serologic test results we withheld from the specialists and they were asked to categorize lesions by characteristics common to target-like and non–target-like lesions. Lesions with the classic bull’s-eye appearance, with central clearing and peripheral erythema, were classified as classic EM; those with uniform red or red-blue or other appearance and lacking central clearing were classified as possible atypical EM. If any lesion of a multiple lesion set was classic in appearance, we categorized the rash as classic EM. Of the 14 patients with positive PCR, 10 had nonclassic EM (Figure) and 4 had classic, target-like EM. Atypical rashes varied from those close to classic EM to those resembling lesions more common in other conditions (e.g., insect or spider bites) and, consequently, prone to misdiagnosis.
Figure

Atypical erythema migrans lesion on a patient with PCR-positive result for Borrelia burgdorferi infection. The rash was not considered typical because it lacked central clearing and peripheral erythema. The differential diagnosis included a contact dermatitis and arthropod bite. At the initial examination, this patient was seronegative for B. burgdorferi by 2-tiered criteria. Three weeks after therapy, the patient had positive results for ELISA and IgM Western blot and negative results for IgG Western blot, providing evidence of seroevolution (i.e., increasing antibody titer and/or increase in band intensity or appearance of new antigen bands to B. burgdorferi).

Atypical erythema migrans lesion on a patient with PCR-positive result for Borrelia burgdorferi infection. The rash was not considered typical because it lacked central clearing and peripheral erythema. The differential diagnosis included a contact dermatitis and arthropod bite. At the initial examination, this patient was seronegative for B. burgdorferi by 2-tiered criteria. Three weeks after therapy, the patient had positive results for ELISA and IgM Western blot and negative results for IgG Western blot, providing evidence of seroevolution (i.e., increasing antibody titer and/or increase in band intensity or appearance of new antigen bands to B. burgdorferi). Depending on the appearance of an atypical rash, the differential diagnosis could include contact dermatitis, arthropod bite, or, in cases with annular lesions, fixed drug eruptions, granuloma annulare, cellulitis, dermatophytosis, or systemic lupus erythematosus (). In addition, a diagnosis can be more challenging when there are multiple skin lesions rather than a single lesion and in a pattern unfamiliar to a general practitioner. Multiple textbooks and websites have featured pictures of EM as a bull’s-eye lesion (Technical Appendix). This emphasis on target-like lesions may have inadvertently contributed to an underappreciation for atypical skin lesions caused by Lyme disease. Nevertheless, physician recognition of Lyme disease–associated EM is essential because current approved laboratory tests may not identify B. burgdorferi in the first few weeks of infection (), when an accurate diagnosis can lead to early curative therapy. Separate studies found different percentages of atypical Lyme disease–associated rashes (,,); each was lower than the percentage found in our study. Our study has several limitations: it encompassed only 1 recruitment season, 1 geographic site, and a small number of patients. The sensitivity of PCR for blood specimens is improving (); however, PCR may have missed some acute cases in our study for reasons cited below. Therefore, these patients should not obligatorily be considered as representative of all acute Lyme disease patients. Our study results serve as an impetus for studying more patients with systemic and nonsystemic signs and symptoms over multiple seasons and geographic areas and for including PCR analysis of skin lesions in future studies. PCR of skin biopsy samples may provide insight as to whether a negative blood PCR is the result of infection with a skin-restricted strain () in patients in whom bacterial dissemination is not expected or a result of low copy number of B. burgdorferi in the blood sample. Our results serve as a reminder that patients with early Lyme disease may have an atypical rash, not the classic (textbook) bull’s-eye lesion. Close observation and a detailed history of whether the rash is enlarging, has enlarged, or is spreading should be part of the consideration of the diagnosis. Observation for extracutaneous signs of early infection, such as cranial seventh nerve palsy (Bell’s palsy) or meningitis, is also essential. In summary, the EM rash of Lyme disease can have an atypical appearance. Thus, clinicians should consider Lyme disease in the differential diagnosis of patients who have a rash that may not be classic EM and who have been in areas where Lyme disease occurs.

Technical Appendix

Classic Lyme disease erythema migrans rash.
  9 in total

1.  Recognition and treatment of erythema migrans: are we off target?

Authors:  Robert B Nadelman; Gary P Wormser
Journal:  Ann Intern Med       Date:  2002-03-19       Impact factor: 25.391

Review 2.  Lyme disease.

Authors:  B W Berger; R L Lesser
Journal:  Dermatol Clin       Date:  1992-10       Impact factor: 3.478

3.  Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans.

Authors:  Robert P Smith; Robert T Schoen; Daniel W Rahn; Vijay K Sikand; John Nowakowski; Dennis L Parenti; Mary S Holman; David H Persing; Allen C Steere
Journal:  Ann Intern Med       Date:  2002-03-19       Impact factor: 25.391

Review 4.  Erythema migrans.

Authors:  B W Berger
Journal:  Clin Dermatol       Date:  1993 Jul-Sep       Impact factor: 3.541

5.  Four clones of Borrelia burgdorferi sensu stricto cause invasive infection in humans.

Authors:  G Seinost; D E Dykhuizen; R J Dattwyler; W T Golde; J J Dunn; I N Wang; G P Wormser; M E Schriefer; B J Luft
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

6.  Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin.

Authors:  B W Berger; R C Johnson; C Kodner; L Coleman
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

Review 7.  Misdiagnosis of erythema migrans.

Authors:  H M Feder; D L Whitaker
Journal:  Am J Med       Date:  1995-10       Impact factor: 4.965

8.  Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

Authors:  A C Steere; V K Sikand; F Meurice; D L Parenti; E Fikrig; R T Schoen; J Nowakowski; C H Schmid; S Laukamp; C Buscarino; D S Krause
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

9.  Direct molecular detection and genotyping of Borrelia burgdorferi from whole blood of patients with early Lyme disease.

Authors:  Mark W Eshoo; Christopher C Crowder; Alison W Rebman; Megan A Rounds; Heather E Matthews; John M Picuri; Mark J Soloski; David J Ecker; Steven E Schutzer; John N Aucott
Journal:  PLoS One       Date:  2012-05-08       Impact factor: 3.240

  9 in total
  15 in total

1.  Accuracy of Clinician Suspicion of Lyme Disease in the Emergency Department.

Authors:  Lise E Nigrovic; Jonathan E Bennett; Fran Balamuth; Michael N Levas; Rachel L Chenard; Alexandra B Maulden; Aris C Garro
Journal:  Pediatrics       Date:  2017-12       Impact factor: 7.124

2.  Decorin binding proteins A and B in the serodiagnosis of Lyme disease in North America.

Authors:  Paul M Arnaboldi; Mariya Sambir; Raymond J Dattwyler
Journal:  Clin Vaccine Immunol       Date:  2014-08-13

3.  Evaluation of a Novel Microarray Immunoblot Assay for Detection of IgM- and IgG-Class Antibodies to Borrelia burgdorferi.

Authors:  Elitza S Theel; Marisa Sorenson; Dane Granger
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

4.  Expanding Access to Biospecimens for Lyme Disease Test Development.

Authors:  John L Schmitz
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

5.  Lyme carditis presenting with an atypical rash.

Authors:  Dennys Franco-Avecilla; Cynthia Yeung; Adrian Baranchuk
Journal:  CMAJ       Date:  2020-05-25       Impact factor: 8.262

6.  Molecular Testing of Serial Blood Specimens from Patients with Early Lyme Disease during Treatment Reveals Changing Coinfection with Mixtures of Borrelia burgdorferi Genotypes.

Authors:  Michael R Mosel; Heather E Carolan; Alison W Rebman; Steven Castro; Christian Massire; David J Ecker; Mark J Soloski; John N Aucott; Mark W Eshoo
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 7.  Lyme Disease Frontiers: Reconciling Borrelia Biology and Clinical Conundrums.

Authors:  Vladimir V Bamm; Jordan T Ko; Iain L Mainprize; Victoria P Sanderson; Melanie K B Wills
Journal:  Pathogens       Date:  2019-12-16

Review 8.  Quantitative multiplexed strategies for human Lyme disease serological testing.

Authors:  Eunice Chou; Armond Minor; Nathaniel C Cady
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-01

9.  Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease.

Authors:  Samiksha Nayak; Archana Sridhara; Rita Melo; Luciana Richer; Natalie H Chee; Jiyoon Kim; Vincent Linder; David Steinmiller; Samuel K Sia; Maria Gomes-Solecki
Journal:  Sci Rep       Date:  2016-10-11       Impact factor: 4.379

10.  Severity of chronic Lyme disease compared to other chronic conditions: a quality of life survey.

Authors:  Lorraine Johnson; Spencer Wilcox; Jennifer Mankoff; Raphael B Stricker
Journal:  PeerJ       Date:  2014-03-27       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.